These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

415 related items for PubMed ID: 21960212

  • 1. Targeting cancer with small-molecular-weight kinase inhibitors.
    Fabbro D, Cowan-Jacob SW, Möbitz H, Martiny-Baron G.
    Methods Mol Biol; 2012; 795():1-34. PubMed ID: 21960212
    [Abstract] [Full Text] [Related]

  • 2. 25 years of small molecular weight kinase inhibitors: potentials and limitations.
    Fabbro D.
    Mol Pharmacol; 2015 May; 87(5):766-75. PubMed ID: 25549667
    [Abstract] [Full Text] [Related]

  • 3. Role of tyrosine kinase inhibitors in cancer therapy.
    Arora A, Scholar EM.
    J Pharmacol Exp Ther; 2005 Dec; 315(3):971-9. PubMed ID: 16002463
    [Abstract] [Full Text] [Related]

  • 4. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S, Djelloul S, Raymond E.
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [Abstract] [Full Text] [Related]

  • 5. Inhibitors of protein kinase signaling pathways: emerging therapies for cardiovascular disease.
    Force T, Kuida K, Namchuk M, Parang K, Kyriakis JM.
    Circulation; 2004 Mar 16; 109(10):1196-205. PubMed ID: 15023894
    [Abstract] [Full Text] [Related]

  • 6. Kinases as targets in the treatment of solid tumors.
    Giamas G, Man YL, Hirner H, Bischof J, Kramer K, Khan K, Ahmed SS, Stebbing J, Knippschild U.
    Cell Signal; 2010 Jul 16; 22(7):984-1002. PubMed ID: 20096351
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Kinase domain mutations in cancer: implications for small molecule drug design strategies.
    Bikker JA, Brooijmans N, Wissner A, Mansour TS.
    J Med Chem; 2009 Mar 26; 52(6):1493-509. PubMed ID: 19239229
    [No Abstract] [Full Text] [Related]

  • 11. Mechanisms of drug inhibition of signalling molecules.
    Sebolt-Leopold JS, English JM.
    Nature; 2006 May 25; 441(7092):457-62. PubMed ID: 16724058
    [Abstract] [Full Text] [Related]

  • 12. Protein kinase inhibitors as a therapeutic modality.
    Levitzki A.
    Acc Chem Res; 2003 Jun 25; 36(6):462-9. PubMed ID: 12809533
    [Abstract] [Full Text] [Related]

  • 13. Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy.
    Li R, Morris SW.
    Med Res Rev; 2008 May 25; 28(3):372-412. PubMed ID: 17694547
    [Abstract] [Full Text] [Related]

  • 14. Protein kinases: From targets to anti-cancer drugs.
    Cruzalegui F.
    Ann Pharm Fr; 2010 Jul 25; 68(4):254-9. PubMed ID: 20637357
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Novel inhibitors of the PI3K family.
    Carnero A.
    Expert Opin Investig Drugs; 2009 Sep 25; 18(9):1265-77. PubMed ID: 19589091
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.